Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will participate in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, starting at 4:30 p.m. ET. The conference will feature a corporate overview presentation. A live webcast and replay are available on Viridian's investor relations website.

Viridian focuses on innovative treatments for serious diseases, with its leading candidate, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease. The second candidate, VRDN-002, is designed for convenient subcutaneous administration.

WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, which includes a presentation beginning at 4:30 p.m. ET.

21st Annual Needham Virtual Healthcare Conference
Format:	Corporate Overview
Date:	Thursday, April 14, 2022
Time:	4:30 p.m. ET
Webcast Link

The live webcast and a replay of the presentation can be accessed under “Events” in the Investors section of the Viridian Therapeutics, Inc. website.

About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com  

FAQ

What is the date and time of Viridian Therapeutics' presentation at the Needham Virtual Healthcare Conference?

Viridian Therapeutics' presentation at the Needham Virtual Healthcare Conference is on April 14, 2022, at 4:30 p.m. ET.

Where can I watch the Viridian Therapeutics presentation from the Needham Conference?

The presentation can be watched live and as a replay on the Investor Relations section of the Viridian Therapeutics website.

What is the primary focus of Viridian Therapeutics?

Viridian Therapeutics focuses on advancing treatments for serious diseases, particularly thyroid eye disease with their candidates VRDN-001 and VRDN-002.

What is VRDN-001 and its target disease?

VRDN-001 is a humanized monoclonal antibody targeting insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.

What is the unique feature of VRDN-002?

VRDN-002 incorporates half-life extension technology and is designed for low-volume, subcutaneous injections.